Table 2.

This table illustrates the wide variation in troponin-I and troponin-T assays, troponin values, and study sizes. Although not directly comparable, we have converted the levels to [ng/L] here for simplicity. Peak troponin values in high-dose chemotherapy studies reached 1980 ng/L; peak values in low-dose studies 11–120 ng/L; study sizes ranged from 19 to 703 participants. Studies routinely classified 30–40% of patients as ‘troponin-positive’ across various generations of troponin assays with differing cut off values. (TnI = troponin-I, TnT = troponin-T)

Study	Patient mix	M:F Age	Trop+/ sample size (% positive)	Baseline Trop+	Tn values (ng/L)	Troponin Cut off (as ng/L)	Troponin assay
Cardinale 2000 [50]	Advanced cancer high dose chemoi	39:165 45 ± 10y	65/204 (32%)	0%	1000 ± 400 Delta EF -18%	500	Stratus II TnI
Cardinale 2002 [51]	Breast CA with HDC2	211 F 46 ± 11y	70/211 (33% )	0%	900 ± 500	500	Stratus II TnI
Cardinale 2004 [48]	Advanced cancer with high dose chemo	216:487 47 ± 12y	208/703 (30% )	0%	E: 160 ± 240 Event 1%, 37%, 84% See below	80	Stratus CS Tn I
Sandri 2003 [52]	Advanced cancer high dose chemo	42:137 47 ± 11y	(32% ) Delta EF −18%	1%	tn + 630 ± 540 [80–1980] tn neg =39 ± 19	80	Stratus II CS Tn I
Auner 2003 [47]	Haematological adults	32:46 58y	78 (15% ) Delta EF >10%	0%	Med 40; [30–120]	30	Roche ElecIII TnT
Lipshultz [53]	ALL children Dox v Dex + Dexraz RCT	120:86 7.4 y	55/158 (35%).	12/119 a (10%)	Tn + 50% Tn++32% Dex 21%, 10%	10 + 25++	Roche ElecsysTnT
Kilickap 2005 [49]	Advanced haem CA with high dose chemo	20:21 44y	(34%)	N = 1 (16 ng/L)		10? 100 Error in paper	Roche ElecIIITnT
Haney [54]	Breast CA	22 F	41% (9/22)	n/a	Peak 60 ng/L Cycle 6: 50% Tn+	Tn+ > 12 ng/L; TnT+ 22/ samples 91	Roche TnT
Katsurada [55]	Breast CA anthracycline + Herceptin	19F only Age N/A	N = 19 hsTnT values	N/A	11 +/− 7.8 4 +/− 1.4	14	Roche hs-TnT